CVRx enrolls first patient in BENEFIT-HF trial to expand Barostim heart failure therapy use

CVRx, Inc. announced the enrollment of the first patient in the BENEFIT-HF trial, a major study testing Barostim therapy in a larger heart failure patient group. The trial will enroll 2,500 patients across 150 centers in the US and Germany, aiming to evaluate mortality and heart failure events. If successful, it could triple the eligible patient population for Barostim, broadening access to this FDA-approved neuromodulation device. The trial is expected to run through 2032, potentially strengthening Barostim's role in heart failure treatment.